A Study Evaluating the Efficacy and Safety of Tislelizumab Versus Chemotherapy in Advanced Non-Squamous Non-small Cell Lung Cancer

Exclusion Criteria

• •1. Diagnosed with NSCLC but with epidermal growth factor receptor (EGFR)-sensitizing mutation or anaplastic lymphoma kinase (ALK) gene translocation
• •2. Received any approved systemic anticancer therapy within 28 days prior to the initiation of study treatment
• •3. Received prior treatment with EGFR inhibitors or ALK inhibitors
• •4. Received prior therapies targeting programmed cell death protein-1 (PD-1) or programmed cell death protein ligand-1 (PD-L1)
• •5. With history of interstitial lung disease, non-infectious pneumonitis or uncontrolled systemic diseases
• •6. Clinically significant pericardial effusion
• •7. Severe infections, active leptomeningeal disease or uncontrolled, untreated brain metastasis
• •8. Any major surgical procedure ≤ 28 days before randomization
• •9. Human immunodeficiency virus (HIV) infection
• •10. Participants with untreated hepatitis B or C virus (HBV/HCV)
• •11. Active autoimmune diseases or history of autoimmune diseases
• •12. History of allergic reactions to chemotherapy